# The Role of Simvastatin in the Epithelial-Mesenchymal Transition Process of Breast Cancer

> **NCT05550415** · PHASE2 · RECRUITING · sponsor: **Indonesia University** · enrollment: 26 (estimated)

## Conditions studied

- Triple Negative Breast Cancer
- Chemotherapy Effect
- Simvastatin Adverse Reaction

## Interventions

- **DRUG:** Simvastatin 40mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05550415
- **Lead sponsor:** Indonesia University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-08-19
- **Primary completion:** 2025-05
- **Final completion:** 2025-08
- **Target enrollment:** 26 (ESTIMATED)
- **Last updated:** 2024-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05550415

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05550415, "The Role of Simvastatin in the Epithelial-Mesenchymal Transition Process of Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05550415. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*